Clinical development of Pfs48/45 as transmission blocking vaccine

Clinical development of Pfs48/45 as transmission blocking vaccine

Objectives

Pfs48/45 is the most advanced EU-developed malaria TB vaccine candidate. PF10C is a subunit of Pfs48/45 that has been produced as R0-PF10C.  Immunization with 100% properly folded R0-PF10C induced transmission-blocking activity in 100% of immunized mice.

The objectives of REDMAL are:

1. Manufacture R0-PF10C at cGMP grade 

2. Prepare for clinical trials with R0-PF10C in Africa.

PI Institution(s)

Principal Investigator (PI)

Funding source(s)

Partner(s)

Key facts

  • Dates
    Mar 2010 to Nov 2014
    Funding amount
    $1,151,000

MESA tags

  • Methodology
    Basic science, Enabling technologies & assays
    Theme(s)
    Immune correlates of protection, Tools for elimination